Literature DB >> 32495285

A Novel Classification of Intrahepatic Cholangiocarcinoma Phenotypes Using Machine Learning Techniques: An International Multi-Institutional Analysis.

Diamantis I Tsilimigras1, J Madison Hyer1, Anghela Z Paredes1, Adrian Diaz1, Dimitrios Moris1, Alfredo Guglielmi2, Luca Aldrighetti3, Matthew Weiss4, Todd W Bauer5, Sorin Alexandrescu6, George A Poultsides7, Shishir K Maithel8, Hugo P Marques9, Guillaume Martel10, Carlo Pulitano11, Feng Shen12, Olivier Soubrane13, Bas Groot Koerkamp14, Itaru Endo15, Timothy M Pawlik16,17.   

Abstract

INTRODUCTION: Patients with intrahepatic cholangiocarcinoma (ICC) generally have a poor prognosis, yet there can be heterogeneity in the patterns of presentation and associated outcomes. We sought to identify clusters of ICC patients based on preoperative characteristics that may have distinct outcomes based on differing patterns of presentation.
METHODS: Patients undergoing curative-intent resection of ICC between 2000 and 2017 were identified using a multi-institutional database. A cluster analysis was performed based on preoperative variables to identify distinct patterns of presentation. A classification tree was built to prospectively assign patients into cluster assignments.
RESULTS: Among 826 patients with ICC, three distinct presentation patterns were noted. Specifically, Cluster 1 (common ICC, 58.9%) consisted of individuals who had a small-size ICC (median 4.6 cm) and median carbohydrate antigen (CA) 19-9 and neutrophil-to-lymphocyte ratio (NLR) levels of 40.3 UI/mL and 2.6, respectively; Cluster 2 (proliferative ICC, 34.9%) consisted of patients who had larger-size tumors (median 9.0 cm), higher CA19-9 levels (median 72.0 UI/mL), and similar NLR (median 2.7); Cluster 3 (inflammatory ICC, 6.2%) comprised of patients with a medium-size ICC (median 6.2 cm), the lowest range of CA19-9 (median 26.2 UI/mL), yet the highest NLR (median 13.5) (all p < 0.05). Median OS worsened incrementally among the three different clusters {Cluster 1 vs. 2 vs. 3; 60.4 months (95% confidence interval [CI] 43.0-77.8) vs. 27.2 months (95% CI 19.9-34.4) vs. 13.3 months (95% CI 7.2-19.3); p < 0.001}. The classification tree used to assign patients into different clusters had an excellent agreement with actual cluster assignment (κ = 0.93, 95% CI 0.90-0.96).
CONCLUSION: Machine learning analysis identified three distinct prognostic clusters based solely on preoperative characteristics among patients with ICC. Characterizing preoperative patient heterogeneity with machine learning tools can help physicians with preoperative selection and risk stratification of patients with ICC.

Entities:  

Mesh:

Year:  2020        PMID: 32495285     DOI: 10.1245/s10434-020-08696-z

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  1 in total

1.  Prognostic utility of albumin-bilirubin grade for short- and long-term outcomes following hepatic resection for intrahepatic cholangiocarcinoma: A multi-institutional analysis of 706 patients.

Authors:  Diamantis I Tsilimigras; J Madison Hyer; Dimitrios Moris; Kota Sahara; Fabio Bagante; Alfredo Guglielmi; Luca Aldrighetti; Sorin Alexandrescu; Hugo P Marques; Feng Shen; B Groot Koerkamp; Itaru Endo; Timothy M Pawlik
Journal:  J Surg Oncol       Date:  2019-04-25       Impact factor: 3.454

  1 in total
  4 in total

Review 1.  Systematic Review and Meta-Analysis of Prognostic Factors for Early Recurrence in Intrahepatic Cholangiocarcinoma After Curative-Intent Resection.

Authors:  Woo Jin Choi; Phil J Williams; Marco P A W Claasen; Tommy Ivanics; Marina Englesakis; Steven Gallinger; Bettina Hansen; Gonzalo Sapisochin
Journal:  Ann Surg Oncol       Date:  2022-02-18       Impact factor: 5.344

Review 2.  Challenges and Opportunities for Treating Intrahepatic Cholangiocarcinoma.

Authors:  Nikolaos Serifis; Diamantis I Tsilimigras; Daniel J Cloonan; Timothy M Pawlik
Journal:  Hepat Med       Date:  2021-11-02

Review 3.  Artificial intelligence and cholangiocarcinoma: Updates and prospects.

Authors:  Hossein Haghbin; Muhammad Aziz
Journal:  World J Clin Oncol       Date:  2022-02-24

Review 4.  Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma.

Authors:  Clifford Akateh; Aslam M Ejaz; Timothy Michael Pawlik; Jordan M Cloyd
Journal:  World J Hepatol       Date:  2020-10-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.